A study by researchers at Brigham and Women's Hospital, in collaboration with researchers at Harvard TH Chan School of Public Health and the Brown School of Public Health, has found that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than doubled from 2022 to 2023. During the same period, there was a 25.6% decrease in patients undergoing metabolic bariatric surgery to treat obesity.
"Our study provides one of the first national estimates of the decline in utilisation of bariatric metabolic surgery among privately insured patients corresponding to the rising use of blockbuster GLP-1 RA drugs," said senior author, Dr Thomas C Tsai, a metabolic bariatric surgeon in the Department of Surgery at Brigham and Women's Hospital.
Using a national sample of medical insurance claims data from more than 17 million privately insured adults, the researchers identified patients with a diagnosis of obesity without diabetes in 2022–2023.
During the study period, 81,092 patients were prescribed GLP-1 RAs (9.6% aged 18-35 years) and 5,173 patients underwent metabolic bariatric surgery (17.5% aged 18-35 years; p<0.001). Patients with metabolic bariatric surgery were more medically complex than those prescribed GLP-1 RAs or no treatment (18.8% vs 8.2% vs 11.1% with ≥4 comorbidities; p<0.001).
The study found a sharp increase in the share of patients who received GLP-1 RAs during the study period, with GLP-1 RA use increasing 132.6% from the last six months of 2022 to the last six months of 2023 (from 1.89 to 4.41 patients per 1,000 patients, Figure 1 B)). Meanwhile, there was a 25.6% decrease in use of bariatric metabolic surgery during the same period (from 0.22 to 0.16 patients per 1,000 patients, Figure 1 A).
Among the sample of patients with obesity, 94.7% received neither form of treatment during the study period (while 5.0% received GLP-1 RAs and 0.3% received surgery). Compared to patients who were prescribed GLP-1 RAs, patients who underwent surgery tended to be more medically complex.
"For now, metabolic bariatric surgery remains the most effective and durable treatment for obesity. National efforts should focus on improving access to obesity treatment, whether pharmacologic or surgical, to ensure patients can receive optimal care," said Tsai, who is also an assistant professor of Surgery at Harvard Medical School and an assistant professor in Health Policy and Management at Harvard TH Chan School of Public Health.
Tsai notes that while GLP-1 RAs can effectively treat obesity and related conditions (such as diabetes), these medications have been limited by high costs, limited supply, and gastrointestinal side effects that may prompt treatment cessation and subsequent weight regain.
"As patients with obesity increasingly rely on GLP-1s instead of surgical intervention, further research is needed to assess the impact of this shift from surgical to pharmacologic treatment of obesity on long-term patient outcomes," he added. "With the national decline in utilisation of metabolic bariatric surgery and potential closure of bariatric surgery programmes, there is a concern that access to comprehensive multidisciplinary treatment of obesity involving pharmacologic, endoscopic, or surgical interventions may become more limited."
"These results also highlight an opportunity to further expand uptake of surgical and pharmacologic treatments for obesity and related comorbidities," said co-author, Dr Ateev Mehrotra, chair of the Department of Health Services, Policy and Practice at the Brown University School of Public Health. "Metabolic bariatric surgery and GLP-1 RAs are both effective interventions for patients with obesity, yet less than 6% of patients in our study received either form of treatment."
Considering these results, the authors encourage clinicians and policymakers to continue to monitor access to effective obesity treatment amidst a rapidly evolving landscape of treatment options. In addition, further research is needed to understand the trade-offs between use of surgical intervention versus increasingly popular GLP-1 RAs to treat obesity.
The findings were published in the paper, ‘Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management’, published in JAMA Network Open. To access this a paper, please click here
Comments